As of 2:30 PM on the 29th, Seegene is trading at 260,000 KRW, up 1.56% from the previous day. The trading volume is 566,670 shares, which is 75.74% of the previous day's volume. Seegene is known as a company that develops, manufactures, and sells molecular diagnostic reagents.
On September 29, Dalmi Lee, a researcher at SK Securities, stated, "The company's earnings growth is expected to continue until next year. First, in preparation for the colder weather, the export approval for a diagnostic kit capable of simultaneously diagnosing seasonal flu and COVID-19 was obtained this month and is scheduled to be launched soon. Additionally, with the increase in equipment sales, performance improvements are expected not only for COVID-19 but also for other respiratory diagnostic kits, so the earnings growth trend is expected to continue until 2021." He set Seegene's target price at 330,000 KRW.
Over the past five days, individual investors have net purchased 22,468 shares of Seegene, while foreigners and institutions have net sold 21,879 shares and net purchased 3,457 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
